{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:07:35Z","timestamp":1785794855470,"version":"3.56.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jns.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T18:26:13Z","timestamp":1457029573000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Genetic substrates of psychosis in patients with Parkinson's disease: A critical review"],"prefix":"10.1016","volume":"364","author":[{"given":"Abhishek","family":"Lenka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Sundar","family":"Arumugham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.03.005_bb0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2016.03.005_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-009-5240-1","article-title":"Non-Motor Symptoms in Parkinson's Disease","author":"Park","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1017\/S1092852900017284","article-title":"Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms","volume":"13","author":"F\u00e9nelon","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jns.2016.03.005_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"F\u00e9nelon","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.03.005_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","article-title":"Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease","volume":"107","author":"Giladi","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2016.03.005_bb0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"A review of the pathophysiology and treatment of psychosis in Parkinson's disease","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jns.2016.03.005_bb0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","article-title":"Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.005_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S1092852900017296","article-title":"Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?","volume":"13","author":"Zahodne","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jns.2016.03.005_bb0050","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","article-title":"What predicts mortality in Parkinson disease? A prospective population-based long-term study","volume":"75","author":"Forsaa","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.005_bb0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/mi.2.6.363","article-title":"Apolipoprotein E, amyloid, and Alzheimer disease","volume":"2","author":"Bales","year":"2002","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jns.2016.03.005_bb0060","article-title":"Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"3\u201312","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2016.03.005_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2016.03.005_bb0070","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1212\/01.WNL.0000130159.28215.6A","article-title":"APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease","volume":"62","author":"Huang","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1212\/01.WNL.0000138612.24301.32","article-title":"ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD","volume":"63","author":"Chang","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.005_bb0080","first-page":"226","article-title":"The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease","volume":"22","author":"de la Fuente-Fern\u00e1ndez","year":"1993","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2016.03.005_bb0085","series-title":"Apolipoprotein E Epsilon 4 Allele Frequency in Patients with Lewy Body Dementia","author":"Clair","year":"1994"},{"key":"10.1016\/j.jns.2016.03.005_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.45.1.97","article-title":"Apolipoprotein E genotype and Lewy body disease","volume":"45","author":"Lippa","year":"1995","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2016.03.005_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","article-title":"Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study","volume":"58","author":"Goetz","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.20481","article-title":"Apolipoprotein E \u03b54 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations","volume":"20","author":"Camicioli","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.03.005_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2006.12.008","article-title":"Phenotypic associations of tau and ApoE in Parkinson's disease","volume":"414","author":"Papapetropoulos","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2016.03.005_bb0110","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/mds.23806","article-title":"Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease","volume":"26","author":"Factor","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.03.005_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.2005.00535.x","article-title":"Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease","volume":"113","author":"Feldman","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2016.03.005_bb0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.parkreldis.2014.02.001","article-title":"Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status","volume":"20","author":"Monsell","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.jns.2016.03.005_bb0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1013205230142","article-title":"The neurobiology of dopamine signaling","author":"Greengard","year":"2001","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jns.2016.03.005_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","article-title":"Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease","volume":"10","author":"Makoff","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jns.2016.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","article-title":"Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease","volume":"55","author":"Sweet","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","article-title":"Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease","volume":"355","author":"Wang","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2016.03.005_bb0145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00217369","article-title":"A 40-nucleotide repeat polymorphism in the human dopamine transporter gene","volume":"91","author":"Sano","year":"1993","journal-title":"Hum. Genet."},{"key":"10.1016\/j.jns.2016.03.005_bb0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mp.4000921","article-title":"Polymorphisms in the 3\u2032-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression","volume":"7","author":"Miller","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jns.2016.03.005_bb0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-3940(00)01685-2","article-title":"The human dopamine transporter gene: The 5\u2032-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample","volume":"297","author":"Rubie","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2016.03.005_bb0160","first-page":"1","article-title":"Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease","author":"Schumacher-Schuh","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jns.2016.03.005_bb0165","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.WNL.0000068009.32067.A1","article-title":"L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism","volume":"60","author":"Kaiser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.005_bb0170","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1471-4159.2001.00647.x","article-title":"The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons","volume":"79","author":"Michelhaugh","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.03.005_bb0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0893-133X(00)00216-5","article-title":"The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans","volume":"24","author":"Martinez","year":"2001","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jns.2016.03.005_bb0180","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1176\/appi.ajp.157.10.1700","article-title":"Prediction of dopamine transporter binding availability by genotype: A preliminary report","volume":"157","author":"Jacobsen","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2016.03.005_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0893-133X(99)00099-8","article-title":"Genotype influences in vivo dopamine transporter availability in human striatum","volume":"22","author":"Heinz","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jns.2016.03.005_bb0190","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1523\/JNEUROSCI.05-08-01972.1985","article-title":"Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence","volume":"5","author":"Crawley","year":"1985","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.03.005_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0165-6147(91)90558-A","article-title":"Cholecystokinin-dopamine interactions","volume":"12","author":"Crawley","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2016.03.005_bb0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1034\/j.1399-0004.1999.560508.x","article-title":"Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease","volume":"56","author":"Fujii","year":"1999","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jns.2016.03.005_bb0205","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008571-200306000-00008","article-title":"Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease","volume":"13","author":"Wang","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jns.2016.03.005_bb0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.mp.4000705","article-title":"Function of the C-36 to T polymorphism in the human cholecystokinin gene promoter","volume":"5","author":"Hansen","year":"2000","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.jns.2016.03.005_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-9338(99)80719-6","article-title":"The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia","volume":"14","author":"Wei","year":"1999","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.jns.2016.03.005_bb0220","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archneur.61.8.1280","article-title":"Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system","volume":"61","author":"Goldman","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0225","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/mds.23655","article-title":"Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations","volume":"26","author":"Goldman","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.03.005_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","article-title":"Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options","volume":"16","author":"Ludolph","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0235","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","article-title":"Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia","volume":"225","author":"Wills","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2016.03.005_bb0240","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.neuint.2012.06.014","article-title":"Scaffold protein Homer 1: implications for neurological diseases","volume":"61","author":"Luo","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jns.2016.03.005_bb0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1471-4159.2002.00869.x","article-title":"Modulation of synaptic signalling complexes by Homer proteins","volume":"81","author":"Thomas","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.03.005_bb0250","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/386284a0","article-title":"Homer: a protein that selectively binds metabotropic glutamate receptors","volume":"386","author":"Brakeman","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.03.005_bb0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainres.2006.11.011","article-title":"The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens","volume":"1131","author":"Yamada","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2016.03.005_bb0260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000230689","article-title":"HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms","volume":"59","author":"De Luca","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jns.2016.03.005_bb0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/tpj.2013.37","article-title":"Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients","volume":"14","author":"Schumacher-Schuh","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jns.2016.03.005_bb0270","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2016.03.005_bb0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(94)90259-3","article-title":"Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease","volume":"231","author":"Konings","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jns.2016.03.005_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. NZ J. Med."},{"key":"10.1016\/j.jns.2016.03.005_bb0285","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2006.10.018","article-title":"Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease","volume":"252","author":"Lin","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.03.005_bb0290","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2008.08.017","article-title":"Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects","volume":"276","author":"Pascale","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.03.005_bb0295","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jns.2016.03.005_bb0300","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","article-title":"Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease","volume":"29","author":"Pritchard","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.03.005_bb0305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00004850-199210002-00003","article-title":"Serotonin and psychiatric disorders","volume":"7","author":"Lopez-Ibor","year":"1992","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2016.03.005_bb0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neulet.2007.06.028","article-title":"Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes","volume":"422","author":"Kiferle","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2016.03.005_bb0315","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jagp.2012.11.001","article-title":"Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias","volume":"22","author":"Creese","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry."},{"key":"10.1016\/j.jns.2016.03.005_bb0320","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane-bound catechol O- methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jns.2016.03.005_bb0325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eurpsy.2007.02.002","article-title":"Role of the COMT gene Val158Met polymorphism in mental disorders: a review","volume":"22","author":"Hos\u00e1k","year":"2007","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.jns.2016.03.005_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2012.09.062","article-title":"No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias","volume":"531","author":"Creese","year":"2012","journal-title":"Neurosci. Lett."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1630137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1630137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T02:41:21Z","timestamp":1567651281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X1630137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":66,"alternative-id":["S0022510X1630137X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.005","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic substrates of psychosis in patients with Parkinson's disease: A critical review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}